Status:
UNKNOWN
Effectiveness and Safety of Pigment Solution Program (PSP) as Adjuvant Therapy in Melasma
Lead Sponsor:
Dr.dr.Irma Bernadette, SpKK (K)
Collaborating Sponsors:
Menarini Group
Conditions:
Melasma
Eligibility:
FEMALE
30-60 years
Phase:
NA
Brief Summary
This research is a clinical study with a single-blind randomized clinical trial design (randomized controlled trial) in multicenters at two Dermatology and Venereology Education centers in Indonesia. ...
Detailed Description
Melasma is one of the most common hyperpigmentary dermatoses, found mostly in Asian or Hispanic people living in tropical areas. The goal of melasma treatment is to remove existing pigmentation and t...
Eligibility Criteria
Inclusion
- women aged 30-60 years
- Fitzpatrick skin phototype IV-V
- Diagnosis of epidermal, mixed and dermal types of Melasma
Exclusion
- Are pregnant or breastfeeding
- Use other lightening agents, both oral and topical
- Allergy to PSP content
- Use of other topical therapies for skin disorders may interfere with the evaluation of melasma conditions
- Suffering from other skin diseases such as acne, dermatitis
- Using hormonal birth control
Key Trial Info
Start Date :
September 25 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT06174545
Start Date
September 25 2023
End Date
December 31 2023
Last Update
December 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rumah Sakit Umum Pusat Nasional Dr. Cipto Mangunkusumo
Jakarta Pusat, DKI Jakarta, Indonesia, 10430